Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Hepatol. Jun 27, 2025; 17(6): 108100
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.108100
Table 1 Patient characteristics, n (%)
Characteristics
Short-course treatment (< 14 days) (n = 19)
Long-course treatment (≥ 14 days) (n = 25)
P value
Age (median, IQR)78.0 (71.0-85.0)75.0 (69.0-84.0)0.667
Sex (male)13 (68.4)14 (56.0)0.599
Co-morbidities
Cerebrovascular disease4 (21.1)6 (24.0)1.000
Chronic pulmonary disease4 (21.1)6 (24.0)1.000
Congestive heart failure2 (10.5)3 (12.0)1.000
Chronic liver disease1 (5.3)3 (12.0)0.622
Chronic kidney disease (serum creatinine > 1.5 mg/dL)2 (10.5)
4 (16.0)
0.684
Diabetes mellitus9 (47.4)9 (36.0)0.653
Rheumatic disease1 (5.3)0 (0)0.432
Malignancy1 (5.3)4 (16.0)0.370
Charlson Comorbidity Index (median, IQR)5.0 (4.5-7.0)6.0 (4.0-8.0)0.839
Use of other immunosuppressive agents or chemotherapy0 (0)1 (4.0)1.000
Use of glucocorticoids0 (0)2 (8.0)0.498
Tokyo Guideline 18 severity grading0.924
Grade Ⅰ7 (36.8)9 (36.0)
Grade Ⅱ4 (21.1)4 (16.0)
Grade Ⅲ8 (42.1)12 (48.0)
Quick Sepsis-Related Organ Failure Assessments (median, range)1 (0-3)2 (0-3)0.149
intensive care unit admission3 (15.8)7 (28.0)0.474
Use of vasopressor2 (10.5)8 (32.0)0.148
White blood cells at diagnosis (/mm3) (mean, range)9620 (2800-22900)12220 (3500-33100)0.217
C-reactive protein at diagnosis (mg/dL) (mean, range)7.09 (0.04-23.5)7.01 (0.05-29.0)0.915
Total bilirubin at diagnosis (mg/dL, mean, range)3.36 (1.0-7.4)3.18 (0.5-11.0)0.633
Body temperature (°C) (mean, range)37.9 (36.7-39.7)38.3 (36.6-40.7)0.229
Cause0.691
Stone16 (84.2)20 (80.0)
Diverticulum1 (5.3)3 (12.0)
Stent obstruction1 (5.3)2 (8.0)
Others1 (5.3)0 (0)
Acute cholecystitis9 (47.4)9 (36.0)0.653
Acute pancreatitis5 (26.3)3 (12.0)0.262
Heart valve disease7 (36.8)8 (32.0)0.988
Nosocomial onset1 (5.3)2 (8.0)1.000
Intravascular devices2 (10.5)2 (8.0)1.000
Auscultation of murmur0.844
Yes3 (16.7)2 (8.7)
No15 (83.3)21 (91.3)
Persistent fever for 7 days or more0 (0)0 (0)
Echocardiography7 (36.8)18 (72.0)0.042
Number of positive blood culture0.005
113 (68.4)6 (24.0)
26 (31.6)19 (76.0)
Follow-up of blood culture1.000
Positive0 (0)0 (0)
Negative4 (100)13 (100)
Causative organism
Polymicrobial15 (79.0)17 (68.0)0.507
Enterococcus sp.13 (68.4)16 (64.0)1.000
Enterococcus faecalis4 (21.1)3 (12.0)0.443
Enterococcus faecium3 (15.8)2 (8.0)0.638
Streptococcus sp.6 (31.6)8 (32.0)1.000
Others1 (5.3)2 (8.0)1.000
Antibiotics
Penicillin9 (47.4)23 (92.0)0.002
Cephalosporin13 (68.4)16 (64.0)1.000
Carbapenem2 (10.5)4 (16.0)0.684
Clindamycin8 (42.1)7 (28.0)0.511
Glycopeptide2 (10.5)11 (44.0)0.021
Fluoroquinolone5 (26.3)7 (28.0)1.000
Linezolid1 (5.3)0 (0)0.432
Metronidazole2 (10.5)1 (4.0)0.570
Aminoglycoside1 (5.3)0 (0)0.432
Time to drainage0.710
≤ 24 hours15 (78.9)21 (84.0)
> 24 hours4 (21.1)4 (16.0)
Duration of effective antibiotics days (median, IQR)9.0 (2.5-11.0)16.0 (15.0-19.0)< 0.001
Duration of effective intravenous antibiotics days (median, IQR)8.0 (0.0-10.0)12.0 (8.0-16.0)0.001